Clinical Trial

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally to adults with advanced or metastatic solid tumors with certain KRAS mutations.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2026-03-03; most recent amendment 2026-06-26.
Status change: Not Yet Recruiting → Recruiting 2026-03-20
Trial Details
NCT Number NCT07458347
Lead Sponsor Kestrel Therapeutics, Inc.
Conditions KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant Colorectal Cancer (CRC), Other KRAS-mutant Solid Tumors
Enrollment 145 participants
Start Date 2026-04-21
Primary Completion 2027-06 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-29